For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.
You may also be interested in...
Another State Approves Pharmacy Access To Hormonal Contraceptives
Indiana allows pharmacists, through a standing order from state health agency, to prescribe some hormonal contraceptives in pill or patch form. American College of Obstetricians and Gynecologists among recent supporters of OTC approval in comments to FDA.
What’s Next? Five Things To Look Out For In May
Generics Bulletin previews the most notable and anticipated events for May 2023.
US Q1 Consumer Health Earnings Preview: Lifted By Welcome Changes, Or Slowed By Surprises?
An end to US COVID-19 PHE on 10 April doesn’t end inflationary pressure on prices for consumer packaged goods. OTC, supplements and personal care product firms could be reporting consumers during Q1 were going along with price increases, opting for less expensive options or buying less.